You are here

  • Home
  • Archive
  • Volume 10, Issue 6
  • Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression

 

Online download statistics by month:

Online download statistics by month: June 2022 to February 2026

AbstractFullPdf
Jun 202242042888
Jul 2022261266111
Aug 202220320757
Sep 202216016536
Oct 202221421549
Nov 202214714845
Dec 2022979733
Jan 2023909023
Feb 20239810057
Mar 2023808148
Apr 2023979934
May 2023697137
Jun 2023727223
Jul 2023798042
Aug 2023545430
Sep 2023485121
Oct 2023535328
Nov 2023707029
Dec 2023646427
Jan 2024596026
Feb 2024787849
Mar 2024808047
Apr 2024585836
May 2024858545
Jun 202410710935
Jul 2024888839
Aug 20244846134
Sep 2024646529
Oct 2024696928
Nov 2024666832
Dec 2024838542
Jan 2025717430
Feb 202516516645
Mar 2025737434
Apr 202511311352
May 2025808070
Jun 2025454579
Jul 2025220
Oct 2025111
Feb 2026110
Total381238581671